<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Leverage Shares 2x Long Hood Daily Etf — News on 6ix</title>
    <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf</link>
    <description>Latest news and press releases for Leverage Shares 2x Long Hood Daily Etf on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/leverage-shares-2x-long-hood-daily-etf" rel="self" type="application/rss+xml" />
    <item>
      <title>Oxford Lane Capital Corp. Prices Preferred Stock Offering</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/oxford-lane-capital-corp-prices-preferred-stock-offering-30</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/oxford-lane-capital-corp-prices-preferred-stock-offering-30</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>GREENWICH, Conn., March 13, 2026 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq GS: OXLC, OXLCP, OXLCL, OXLCO, OXLCZ, OXLCN, OXLCI and OXLCG) (the</description>
    </item>
    <item>
      <title>SGN Announces BlockchAIn Has Signed LOI for 5 MW AI Infrastructure Deployment, Over $100 Million in Expected Contract Value During Initial Term</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sgn-announces-blockchain-has-signed-loi-for-5-mw-ai-infrastructure-deployment-over-dollar100-million-in-expected-contract-value-during-initial-term-14</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sgn-announces-blockchain-has-signed-loi-for-5-mw-ai-infrastructure-deployment-over-dollar100-million-in-expected-contract-value-during-initial-term-14</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Scottsdale, AZ, March 13, 2026 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports”, “SGN” or the “Company”) (NYSE American: SGN), in connection</description>
    </item>
    <item>
      <title>Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-7</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-7</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline</description>
    </item>
    <item>
      <title>SunPower Completes the Integration of Sunder Energy</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sunpower-completes-the-integration-of-sunder-energy-23</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sunpower-completes-the-integration-of-sunder-energy-23</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Integration Strengthens New Engine of Growth, Quality Standards, and Gains U.S. No 4 Spot OREM, Utah, March 13, 2026 (GLOBE NEWSWIRE) -- SunPower Inc.</description>
    </item>
    <item>
      <title>Beyond Oil Announces Results of Meeting of Shareholders</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/beyond-oil-announces-results-of-meeting-of-shareholders-15</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/beyond-oil-announces-results-of-meeting-of-shareholders-15</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, March 13, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech</description>
    </item>
    <item>
      <title>MicroCloud Hologram Inc. (NASDAQ: HOLO) 2025 Annual Performance Forecast: Investment Income Fluctuations Lead to Annual Loss, Core Business Maintains Steady Growth</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-12</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-12</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>SHENZHEN, China, March 13, 2026 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), (&quot;HOLO&quot; or the &quot;Company&quot;), a technology service provider, has</description>
    </item>
    <item>
      <title>TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-19</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-19</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE</description>
    </item>
    <item>
      <title>P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-2</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-2</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>HENDERSON, Nev.--(BUSINESS WIRE)-- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health</description>
    </item>
    <item>
      <title>Equillium Announces $35 Million Financing with RA Capital Management</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-17</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-17</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected</description>
    </item>
    <item>
      <title>Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-6</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-6</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific</description>
    </item>
    <item>
      <title>SAGT Launches SAGE AI, Secures USD 11 Million in Enterprise Contracts to Drive AI-Powered Restaurant Transformation Across Southeast Asia</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sagt-launches-sage-ai-secures-usd-11-million-in-enterprise-contracts-to-drive-ai-powered-restaurant-transformation-across-southeast-asia-13</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sagt-launches-sage-ai-secures-usd-11-million-in-enterprise-contracts-to-drive-ai-powered-restaurant-transformation-across-southeast-asia-13</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Next-Generation AI Platform Leverages Data from Thousands of Locations to Optimize Operations, Forecast Demand, and Capture Rapid Growth in Asia-Pacific’s</description>
    </item>
    <item>
      <title>Covering Millions of Crypto Users, UTime Signs Non-Binding Letter of Intent to Acquire Data Platform “Feixiaohao” for Web3 Infrastructure Expansion</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/covering-millions-of-crypto-users-utime-signs-non-binding-letter-of-intent-to-acquire-data-platform-feixiaohao-for-web3-infrastructure-expansion-18</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/covering-millions-of-crypto-users-utime-signs-non-binding-letter-of-intent-to-acquire-data-platform-feixiaohao-for-web3-infrastructure-expansion-18</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>SHENZHEN, China, March 13, 2026 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO), a global technology company engaged in the design, development, and</description>
    </item>
    <item>
      <title>U.S. Energy Corp. Reports 2025 Results and Highlights Transformation into Integrated Industrial Gas, Energy, and Carbon Management Platform</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-7</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-7</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) -- U.S. Energy Corporation (NASDAQ: USEG, &quot;U.S. Energy&quot; or the &quot;Company&quot;) today reported financial and operating</description>
    </item>
    <item>
      <title>SEALSQ and Parrot Expand Their Strategic Partnership: Parrot to Integrate SEALSQ Post-Quantum Cryptography into Its Next Generation of Secure Drones</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sealsq-and-parrot-expand-their-strategic-partnership-parrot-to-integrate-sealsq-post-quantum-cryptography-into-its-next-generation-of-secure-drones-26</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sealsq-and-parrot-expand-their-strategic-partnership-parrot-to-integrate-sealsq-post-quantum-cryptography-into-its-next-generation-of-secure-drones-26</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Paris, France / Geneva, Switzerland , March 13, 2026 (GLOBE NEWSWIRE) -- Parrot CEO &amp; founder Henri Seydoux together with SEALSQ General Manager Bernard Vian</description>
    </item>
    <item>
      <title>Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-8</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-8</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development</description>
    </item>
    <item>
      <title>SUMA Acquisition Corporation Announces Closing of $172,500,000 Initial Public Offering, Including Full Exercise of Underwriters’ Over-Allotment Option</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/suma-acquisition-corporation-announces-closing-of-dollar172500000-initial-public-offering-including-full-exercise-of-underwriters-over-allotment-option-16</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/suma-acquisition-corporation-announces-closing-of-dollar172500000-initial-public-offering-including-full-exercise-of-underwriters-over-allotment-option-16</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Las Vegas, Nevada, March 13, 2026 (GLOBE NEWSWIRE) -- SUMA Acquisition Corporation (NASDAQ: SUMAU) (the “Company”) today announced the closing of its initial</description>
    </item>
    <item>
      <title>Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-2</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-2</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Achieved Regulatory Milestones for the MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Development Program: U.S. Food and Drug</description>
    </item>
    <item>
      <title>Purple Biotech Announces CEO Transition</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/purple-biotech-announces-ceo-transition-8</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/purple-biotech-announces-ceo-transition-8</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE</description>
    </item>
    <item>
      <title>SBC Medical to Announce Q4 and Full‑Year 2025 Financial Results</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-7</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-7</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>IRVINE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management</description>
    </item>
    <item>
      <title>Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company</title>
      <link>https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-22</link>
      <guid isPermaLink="true">https://6ix.com/company/leverage-shares-2x-long-hood-daily-etf/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-22</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology</description>
    </item>
  </channel>
</rss>